The鈥痬ajority of cancer cases arise from accumulated damage to our genetic material,鈥痑 phenomenon that happens more than 10,000 times a day and can鈥痗ause鈥痬utations to our DNA and lead to uncontrolled cell growth.鈥�
As soon as there is DNA damage, the cell activates a mechanism called the DNA damage response that acts like a call to the emergency services. Proteins rapidly bind damaged DNA to send alarm signals, which will be recognised by other proteins specialised in repairing the damage. In this way, the DNA repair machinery detects and repairs鈥痝enetic damage鈥痶o prevent DNA mutations that contribute to aging and diseases such as cancer. But even after鈥痜our decades of intensive research, that鈥痗ritical process鈥� still remains only partially characterized.
In a new study in , professor 鈥痮f 麻豆传媒鈥檚鈥痙epartments of Pathology and Biochemistry & Molecular Biology鈥痗ollaborated with鈥疍r. Raul Mostoslavsky at the Massachusetts General Hospital and colleagues at the National Cancer Research Center in Spain to use a鈥痗ell imaging and a machine-learning analysis鈥痬ethod to visualise this DNA repair machinery鈥痺ith a degree of detail and precision never achieved鈥痓efore.
鈥淭he combination of machine learning and live-cell imaging really took centre stage in this study by providing novel insights into how our cells prevent cancer-causing mutations,鈥� says Dr. Dellaire.
New techniques, new discoveries
Dr. Dellaire鈥檚 lab began working on the project led by Dr. Mostoslavsky in 2015, shortly after they collaborated on a separate study with David Langenau at Mass General in Boston. For that collaboration, they developed live-cell imaging techniques to visualize DNA repair in cancer cells using multi-colour fluorescence microscopy using a custom-built state-of-the-art spinning disk microscope.
鈥淭his same technique was a perfect fit for this new study of chromatin proteins in DNA repair and has led to the discovery of鈥痵everal new proteins with roles in the repair process,鈥� says Dr. Dellaire (shown above left).
In the first phase, they introduced more than 300 different proteins into the cells and evaluated their ability to interfere with DNA repair in parallel in a single experiment over time. This high-throughput technique, coupled with image-based machine learning, led to the discovery of鈥痭ine new proteins that are involved in DNA repair.
In a second phase of the project, two trainees in the Dellaire laboratory 鈥� former Ph.D. student Dudley Chung and research associate Jayme Salsman 鈥� studied the movement of these novel DNA repair proteins in living cells using a spinning disk confocal microscope equipped with a special laser that damages DNA, which were purchased with funds from the 麻豆传媒 Medical Research Foundation and the Natural Sciences and Engineering Research Council of Canada.
Above, a live HeLa cervical cancer cell is shown before and after DNA damage with a laser, the line between the white arrows shows the recruitment of a DNA repair protein (53BP1) tagged with a red fluorescent protein (Image Credit: Dudley Chung/Graham Dellaire).
This unique approach of combining imaging of DNA repair proteins in live cells and machine learning provides a new tool to better understand cancer and could possibly lead to new treatments.聽For example, the goal of chemotherapy is to kill tumour cells by inducing DNA lesions, which cause cancer cell collapse and death.聽Thus, targeting proteins that help cancer cells repair their DNA could help to make chemotherapy work better and at lower doses.
鈥淏y knowing how DNA lesions occur and how they are repaired, we will learn more about how cancer develops and how we can fight it.鈥疉ny new discovery in DNA repair will help develop better cancer therapies, while protecting our healthy cells,鈥� says researcher and co-author, Barbara Martinez of the National Cancer Research Center.
The research was funded by the Natural Sciences and Engineering Research Council of Canada, the Spanish Ministry of Science and Innovation, the Carlos III Institute of Health, the U.S. National Institutes of Health, the Marie Curie COFUND FP7, Massachusetts General Hospital and the European Research Council.